What sets treatment by Dr. Baum and his team at Bad Berka apart from PRLT offered at other medical centers in Europe is not only a individualized approach to dosimetry and treatment, but also the view that patients should be administered with lower amounts of radioactivity at more frequent and prolonged intervals (3-6 months in between therapies), rather than given a high dose of radiation at shorter intervals.  Dr. Baum and his team have published results of their approach as applied to patients from 2013 through 2016 in the Journal of Nuclear Medicine in 2016.

The individualized approach is made largely possible by the use of the 68-Gallium-PSMA PET/CT scan. The 68-Ga PET/CT scan is used to calculate the Standard Uptake Values (SUV) for all the tumors (with receptors) as well as for diagnostic detection of tumors and post-treatment evaluations of the PRLT. This scan allows the team at Bad Berka in conjunction with other diagnostic tests, to better determine the strength of the dose tailored to each patient's tumor load and renal function.

In addition to facilitating the individualized dosimetry, the 68-Ga-PSMA PET/CT scan adds considerable depth to the diagnostic evaluation. The PSMA-ligund that is radiolabeled with 68-Gallium has a strong affinity for the metastatic castration-resistant lesions. This is important because the ultimate goal is to use as low a dosage as possible to do the most damage to the tumors and the least damage to any organs or other tissue.